Browsing Tag
Race Oncology
2 posts
Racura Oncology (ASX: RAC) stock up 12.21% as MYC silencing data builds case for bisantrene relaunch
MYC is the undruggable cancer gene. Racura Oncology (ASX: RAC) says bisantrene silences it via G4 stabilisation. Three clinical trials, A$19m cash, and a 2027 inflection ahead.
Race Oncology doses first patient in phase 1b/2 AML trial of FluCloZan
Race Oncology has dosed the first patient in the phase 1b/2 trial of its Zantrene (bisantrene dihydrochloride) in…